Loading
A phase 1/2 trial of Glofitamab, Obinutuzumab, Tocilizumab in non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT03075696 by Hoffmann-La Roche, with 940 participants planned, started 2017-02-21 and due to reach its primary completion in 2029-03-30. Interventions recorded: Glofitamab, Obinutuzumab, Tocilizumab. Conditions listed: Non-Hodgkin's Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tocilizumab, Glofitamab, Obinutuzumab, Roche / Genentech.
Shares Tocilizumab, Glofitamab, Obinutuzumab, T-cell engagers (bispecific).
Shares Tocilizumab, Glofitamab, Obinutuzumab, T-cell engagers (bispecific).
Shares Glofitamab, Obinutuzumab, Roche / Genentech, T-cell engagers (bispecific).
Shares Tocilizumab, Roche / Genentech, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Shares Tocilizumab, Glofitamab, T-cell engagers (bispecific), Monoclonal antibodies.
Shares Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Glofitamab, T-cell engagers (bispecific).
Shares Tocilizumab, Roche / Genentech, T-cell engagers (bispecific), Non-Hodgkin lymphoma (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/